Vascular and regenerative medicine
Instead of reducing injury to organs, we now aim to restore full function.
Mainly due to the epidemic occurrence of atherosclerosis and diabetes, a rapidly growing number of people have severe organ damage, especially heart and kidney failure. This is an increasing burden on health care systems all over the world, and the waiting lists for organ transplants are growing. Regenerative medicine holds the promise of alleviating these problems.
Fundamental research has already proven that it is possible to regenerate organs such as the heart, the insulinproducing cells in the pancreas and even parts of the central nervous system using stem cells, growth factors and/or biomaterials. The challenge for the near future is to translate these laboratory results into clinical applications. The Leiden University Medical Center, once the first Dutch hospital to offer renal and bone marrow transplants, is now among the frontrunners in regenerative medicine. Fundamental research groups are focusing on the many unresolved problems in stem cell biology. Experienced multidisciplinary clinical research groups are already conducting clinical trials. A strong interaction between fundamental and clinical research is crucial.
Cell therapy approaches require the highest quality standards in manufacturing. The LUMC’s Good Manufacturing Practice facility offers a protected sterile environment, thus strengthening the connection between fundamental and applied research.
- Wim Fibbe, Professor of Haematology, Leiden University Medical Center
- Christine Mummery, Professor of Developmental Biology, Leiden University Medical Center
- Ton Rabelink, Professor of Nephrology, Leiden University Medical Center
Leiden University Medical Center